1
|
Ulusakarya A, Karray W, Abdou J, Karaboué A, Haydar M, Krimi S, Gumus Y, Almohamad W, Goldschmidt E, Biondani P, Morère J. FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.144] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
2
|
Innominato P, Komarzynski S, Bouchahda M, Ulusakarya A, Haydar M, Karaboué A, Levi F. Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-fluorouracil (F), leucovorin (L) and oxaliplatin (O; chronoIFLO4) combination at home. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Komarzynski S, Lévi F, Ballesta A, Bouchahda M, Haydar M, Ulusakarya A, Morère J, Innominato PF. 1038 OBJECTIVE CORRELATES OF SLEEP COMPLAINT IN CANCER PATIENTS ON CHEMOTHERAPY TELE-MONITORED AT HOME: NIGHT-BY-NIGHT ANALYSIS. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.1037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Arbaud A, Innominato P, Mohammad-Djafari A, Ulusakarya A, Bossevot-Desmaris R, Plessis V, Mocquery M, Bouchoucha D, Beau J, Bouchahda M, Karaboue A, Morère J, Fursse J, Caprino M, Levi F. Detection of Health-Related Warning Signals Through Daily Telemonitoring of Cancer Patients on Multidrug Chemotherapy at Home (European Project Incasa). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Machover D, Delmas-Marsalet B, Misra S, Ulusakarya A, Gumus Y, Frénoy N, Guettier C, Saffroy R, Innominato P, Almohamad W, Brahimi N, Haydar M, Goldschmidt E. Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. Biomed Pharmacother 2010; 64:83-7. [DOI: 10.1016/j.biopha.2009.11.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2009] [Accepted: 11/02/2009] [Indexed: 10/20/2022] Open
|
6
|
Ulusakarya A, Haghighi F, Juin F, Marconi A, Liu XH, Machover D, Uzan G. High number of peripheral blood circulating endothelial progenitor cells (EPCs) in a patient with erythropoietin (EPO) producing renal carcinoma (RC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Ulusakarya
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| | - F. Haghighi
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| | - F. Juin
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| | - A. Marconi
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| | - X.-H. Liu
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| | - D. Machover
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| | - G. Uzan
- Paul Brousse Hosp, Villejuif, France; Inserm Unit 602, Villejuif, France
| |
Collapse
|
7
|
Machover D, Delmas-Marsalet B, Gumus Y, Misra SC, Ulusakarya A, Brahimi N, Goldschmidt E, Frenoy N, Guettier C. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx), and rituximab plus DHAOx (R-DHAOx) for treatment of patients with B-cell non-Hodgkin's lymphoma: Results from two consecutive phase II studies. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Y. Gumus
- Paul Brousse Hospital, Villejuif, France
| | | | | | - N. Brahimi
- Paul Brousse Hospital, Villejuif, France
| | | | - N. Frenoy
- Paul Brousse Hospital, Villejuif, France
| | | |
Collapse
|
8
|
Tejpar S, Van Cutsem E, Gamelin E, Machover D, Soulie P, Ulusakarya A, Laurent S, Vauthier JM, Quinn S, Zacharchuk C. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3579] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Tejpar
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - E. Van Cutsem
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - E. Gamelin
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - D. Machover
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - P. Soulie
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - A. Ulusakarya
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - S. Laurent
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - J. M. Vauthier
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - S. Quinn
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| | - C. Zacharchuk
- University Hospital Gasthuisberg, Leuven, Belgium; Centre Paul Pipin, Angers, France; Hopital Paul Brousse, Villejuif, France; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA
| |
Collapse
|
9
|
Ulusakarya A, Chachaty E, Vantelon JM, Youssef A, Tancrède C, Pico JL, Bourhis JH, Fenaux P, Munck JN. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2002; 1:111-6. [PMID: 11920178 DOI: 10.1038/sj.thj.6200009] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/1999] [Accepted: 09/23/1999] [Indexed: 11/09/2022]
Abstract
INTRODUCTION The incidence of invasive fungal infections is increasing in patients with hematological malignancies. Invasive aspergillosis is one of the most frequently encountered infections with a high mortality rate. New diagnostic tests for invasive aspergillosis such as the detection of Aspergillus galactomannan antigen by a sandwich enzyme-linked immunosorbent assay (ELISA) have recently been described. The objective of this study was to evaluate this assay as a potential surrogate for invasive procedures used to diagnose IA. MATERIALS AND METHODS We analyzed the performance of a commercially available ELISA test which we routinely use for the surveillance of galactomannan antigenemia in patients with hematological malignancies experiencing chemotherapy-induced prolonged neutropenia (ANC < 500/mm(3) for more than 7 days). Serum samples were collected on a weekly basis. Test positivity was defined in accordance with the manufacturer's recommendations. RESULTS Over the 2 year study period, we analyzed 507 samples obtained during 193 neutropenic episodes from 135 patients. Ten, six and two patients were considered to have proven, probable or possible invasive aspergillosis, respectively, based on clinical, radiological or microbiological data. Forty-four positive (Index>1.5) and 26 'undetermined' (1.5 > Index > 1.0) test results were observed in 17 and ten patients respectively. All invasive aspergillosis cases had at least a positive or an undetermined test result. Only one positive and one undetermined result were found in two patients before the onset of clinical or radiological signs suggesting invasive aspergillosis. Sensitivity was 69% and specificity 96% if only positive results are considered; when 'undetermined' test results were combined with positive results, sensitivity attained 100% and specificity 92% suggesting that the cutoff value for positivity can be lowered from 1.5 to 1.0. CONCLUSIONS Although the ELISA test did not appear to play a role in the early diagnosis of invasive aspergillosis and in the anticipation of antifungal therapy in our experience, it clarifies the diagnosis of infection in probable or possible invasive aspergillosis especially when the cutoff value is lowered and is useful for monitoring patients receiving specific therapy.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Antigens, Fungal/blood
- Antineoplastic Agents/adverse effects
- Aspergillosis/blood
- Aspergillosis/diagnosis
- Aspergillosis/etiology
- Aspergillosis, Allergic Bronchopulmonary/blood
- Aspergillosis, Allergic Bronchopulmonary/diagnosis
- Aspergillosis, Allergic Bronchopulmonary/etiology
- Aspergillus/isolation & purification
- Child
- Enzyme-Linked Immunosorbent Assay
- Female
- Galactose/analogs & derivatives
- Hematologic Neoplasms/complications
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Myeloid, Acute/complications
- Lymphoma, Non-Hodgkin/complications
- Male
- Mannans/immunology
- Middle Aged
- Neutropenia/chemically induced
- Neutropenia/microbiology
Collapse
Affiliation(s)
- A Ulusakarya
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, Frénoy N, Emile JF, Debuire B, Guettier C, Farrokhi P, Boulefdaoui B, Norol F, Parquet N, Ulusakarya A, Jasmin C. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol 2001; 12:1439-43. [PMID: 11762817 DOI: 10.1023/a:1012501305214] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Dexamethasone. cytarabine (ara-C), and cisplatin (DHAP) can be used effectively to treat patients with non-Hodgkin's lymphoma (NHL). We hypothesized that substitution of cisplatin by oxaliplatin (L-OHP) could result in less toxicity and greater efficacy. L-OHP is active in patients with lymphoma. It produces mild myelosuppression and is devoid of renal toxicity. We report on a phase II study of dexamethasone, high-dose ara-C, and L-OHP (DHAOx) used to treat patients with NHL who were previously treated with chemotherapy. PATIENTS AND METHODS Fifteen patients were given DHAOx. They had failed to achieve a CR with initial chemotherapy or had recurrent disease. DHAOx consisted of dexamethasone, 40 mg/day (days 1 to 4): L-OHP, 130 mg/m2 (day 1); and ara-C, 2,000 mg/m2 every 12 h (day 2). Treatment was repeated every 21 days. RESULTS Patients received a median of four courses of DHAOx. Myelosuppression and transient sensory peripheral neuropathy were the most prominent toxic effects. Serum creatinine levels did not increase in patients with normal renal function, nor in patients who had renal impairment before DHAOx. The median follow-up time from the start of DHAOx treatment was 17 months. Eight patients (53%) achieved a CR, and three patients (20%) had a PR. Responses were achieved by patients with lymphomas of various histologies that included mainly the follicular subtype, and by patients with and without resistance to prior chemotherapy. None of the eight responders have relapsed from CR at 4+. 6+, 14+, 15+, 19+, 20+, 24+, and 24+ months. They had various types of therapy after DHAOx. Disappearance of molecular markers was observed in all four patients who achieved a CR and whose tumor cells carried molecular abnormalities. CONCLUSION DHAOx possesses characteristics of toxicity which compare favorably to those reported with DHAP, and it is useful as a salvage treatment for patients with NHL. Larger studies are required to establish the therapeutic potential of the regimen.
Collapse
Affiliation(s)
- D Machover
- Department of Hematology and Oncology and the Institut du Cancer et d'Immunogénétique (ICIG), Hospital Paul Brousse, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Vantelon JM, Munck JN, Bourhis JH, Pico JL, Fadel C, Ulusakarya A, Carde P, Fenaux P, Ribrag V. Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. Bone Marrow Transplant 2001; 27:531-6. [PMID: 11313688 DOI: 10.1038/sj.bmt.1702812] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2000] [Accepted: 12/10/2000] [Indexed: 11/09/2022]
Abstract
Ten patients with refractory (n = 8) or early relapsing (n = 2) aggressive non-Hodgkin's lymphoma were enrolled in a pilot study evaluating a high-dose sequential chemotherapy regimen with peripheral blood stem cell (PBSC) support. Five treatment phases were scheduled: phase I (cyclophosphamide + etoposide followed by lenograstim (G-CSF), and a PBSC harvest); phase II (cisplatinum + cytarabine + etoposide followed by lenograstim); phases III and IV (cyclophosphamide + cytarabine + etoposide followed by autologous PBSC infusion and lenograstim); and phase V (carmustine + cytarabine + etoposide + melphalan followed by autologous PBSC infusion and lenograstim). Ten, nine, eight, six and four of the 10 patients received one, two, three, four and five of the five scheduled phases of treatment, respectively. Four patients were withdrawn from the study due to progressive disease and two due to thrombotic microangiopathy (TM). Moreover, in the four patients who completed all treatment phases, an additional case of TM was seen. In all three patients with TM, laboratory studies showed evidence of Coombs negative hemolytic anemia, thrombocytopenia, renal dysfunction and in addition cardiac failure in two patients. TM may be a new dose-limiting toxicity of high-dose sequential chemotherapy followed by repeated PBSC transplantation.
Collapse
Affiliation(s)
- J M Vantelon
- Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ulusakarya A, Terrier P, Regnard JF, de Montpreville V, Munck JN. Extraskeletal osteosarcoma of the mediastinum after treatment of a mediastinal germ-cell tumor. Am J Clin Oncol 1999; 22:609-14. [PMID: 10597747 DOI: 10.1097/00000421-199912000-00013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Three years after four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy for a nonseminomatous germ-cell tumor of the mediastinum followed by complete resection of residual teratoma in a 21-year-old man, a mediastinal recurrence was diagnosed as an extraskeletal osteosarcoma. After unsuccessful chemotherapy and removal of the tumor, the patient died of cerebral metastases. Histologic transformation of the teratomatous components of nonseminomatous germ-cell tumors is an uncommon phenomenon showing a particular aspect of germ-cell tumor biology. We review the literature and discuss the pathogenesis concerning this subject.
Collapse
Affiliation(s)
- A Ulusakarya
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | |
Collapse
|
13
|
Ulusakarya A, Lumbroso J, Casiraghi O, Koscielny S, Vantelon JM, Girinsky T, Tardivon A, Bourhis JH, Dartevelle P, Pico JL, Munck JN. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35:579-86. [PMID: 10609795 DOI: 10.1080/10428199909169622] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Optimal evaluation of residual masses of non Hodgkin's lymphomas (NHL) after chemotherapy is of major importance, and gallium scan (GS) is routinely used for this purpose, particularly for mediastinal sites. However, sensitivity and specificity of GS in this setting has been diversely appreciated and needs to be more accurately defined especially if radiotherapy is not planned. A retrospective analysis selected all the patients treated in a single institution for aggressive NHL who presented a residual mass in the mediastinum after chemotherapy and who were evaluated by GS. The value of GS for distinguishing true complete responses (CR) from partial responses (PR) was analyzed in patients who were either submitted to resection of their residual mass or followed up without further treatment after GS. A residual mass with mean perpendicular diameters measuring 4.1 cm x 2.8 cm was found in 42 patients and was GS positive in 8 cases and negative in 34 cases. After GS, radiotherapy was delivered to 10 patients, but 12 patients underwent resection of their residual mass and 20 were followed up without further treatment. In the patients who did not receive radiotherapy, 3 false positive and 6 false negative GS results were disclosed. The specificity and the sensitivity of GS were 88% and 25%, and its positive predictive value and negative predictive value 40% and 78%, respectively. GS was not sufficiently reliable to evaluate post chemotherapy residual masses. Surgical resection of residual masses should be considered particularly in young patients. Patients in true CR should be spared pointless radiotherapy and its late side effects, while patients in PR may benefit from further intensified chemotherapy followed by radiotherapy.
Collapse
MESH Headings
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Combined Modality Therapy
- False Negative Reactions
- False Positive Reactions
- Female
- Follow-Up Studies
- Gallium Radioisotopes
- Humans
- Life Tables
- Lymphoma, Non-Hodgkin/diagnostic imaging
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/mortality
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/radiotherapy
- Lymphoma, Non-Hodgkin/surgery
- Magnetic Resonance Imaging
- Male
- Mediastinal Neoplasms/diagnostic imaging
- Mediastinal Neoplasms/drug therapy
- Mediastinal Neoplasms/mortality
- Mediastinal Neoplasms/pathology
- Mediastinal Neoplasms/radiotherapy
- Mediastinal Neoplasms/surgery
- Neoplasm Staging
- Neoplasm, Residual
- Predictive Value of Tests
- Prognosis
- Radiotherapy, Adjuvant
- Remission Induction
- Retrospective Studies
- Salvage Therapy
- Sensitivity and Specificity
- Survival Analysis
- Thoracotomy
- Tomography, Emission-Computed, Single-Photon
- Treatment Outcome
Collapse
Affiliation(s)
- A Ulusakarya
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Ulusakarya A, Youssef A, Bayle C, Vantelon JM, Munck JN. Plasma cell meningitis after an autograft in a patient with multiple myeloma. Leuk Lymphoma 1999; 34:633-4. [PMID: 10492092 DOI: 10.3109/10428199909058496] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
15
|
|